Verneuil Vanina De Sells 1,403 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 1,403 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $7.20, for a total value of $10,101.60. Following the completion of the transaction, the executive vice president now owns 63,717 shares in the company, valued at approximately $458,762.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 5th, Verneuil Vanina De sold 2,347 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.47, for a total value of $22,226.09.

Vir Biotechnology Trading Down 3.9 %

Shares of Vir Biotechnology stock opened at $9.77 on Friday. The stock has a 50 day moving average of $7.83 and a 200 day moving average of $8.90. Vir Biotechnology, Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same period in the previous year, the business posted ($1.22) earnings per share. The firm’s revenue for the quarter was down 9.8% compared to the same quarter last year. Research analysts predict that Vir Biotechnology, Inc. will post -3.86 earnings per share for the current year.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. grew its stake in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares in the last quarter. Innealta Capital LLC acquired a new position in Vir Biotechnology in the 2nd quarter valued at about $32,000. nVerses Capital LLC acquired a new position in Vir Biotechnology in the 3rd quarter valued at about $56,000. Magnetar Financial LLC purchased a new stake in Vir Biotechnology during the second quarter worth about $95,000. Finally, Quest Partners LLC lifted its position in shares of Vir Biotechnology by 142.1% during the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after purchasing an additional 7,452 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Barclays lowered their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a report on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Monday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).